Agilent announces acquisition of e-msion, early-stage company behind ecd technology that helps accelerate drug development

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced the acquisition of e-msion, an early-stage company behind the innovative electron capture dissociation (ecd) technology known as the exd cell. the exd cell is a compact device for mass spectrometers that enables biological researchers to develop biotherapeutic products more quickly to treat disease.
A Ratings Summary
A Quant Ranking